Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
300725.SZ
HOLDAPPROVEPharmaBlock Sciences (Nanjing), Inc. · Healthcare · China · $1.2B · Avg Vol: $34M/d
PharmaBlock is a specialized CDMO focused on chemistry-based building blocks for drug discovery and development. By designing and manufacturing unique, high-quality intermediates, PharmaBlock embeds itself deeply into the R&D pipelines of global pharmaceutical giants. This creates high switching costs and pricing power. Despite geopolitical noise surrounding Chinese biotech, PharmaBlock's specialized chemistry capabilities make it highly resilient and indispensable for global drug development pipelines.
COMPANY DESCRIPTION
PharmaBlock Sciences (Nanjing), Inc. provides novel chemistry building blocks and contract development and manufacturing organization (CDMO) services for drug discovery and development. The company is a global leader in its niche, offering a proprietary library of thousands of unique building blocks that accelerate drug candidate generation. It operates as a highly specialized partner to top-tier global pharmaceutical and biotechnology companies, leveraging advanced flow chemistry and biocatalysis technologies.
FINANCIAL SUMMARY
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 236M | 255M | 250M | 292M | 7.4% |
| EPS | — | 0.23 | 0.15 | 0.16 | 0.13 | -17.7% |
| Shares | — | 200M | 200M | 200M | 234M | +17.1% |
| Debt | 3M | 232M | 258M | 209M | 17M | 47.8% |
| Equity | — | 393M | 419M | 442M | 931M | 33.3% |
| Op CF | — | 36M | 36M | 45M | 99M | 39.4% |
| Inv CF | — | -88M | -139M | -11M | -26M | — |
| Fin CF | — | 112M | 10M | -69M | -36M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300725.SZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 300725.SZ | PharmaBlock Sciences (Nanjing), Inc.(you) | $1.2B | 60 | HOLD |
| 601089.SS | Beijing Foyou Pharma CO.,LTD | $1.3B | 61 | HOLD |
| 2186.HK | Luye Pharma Group Ltd. | $1.1B | 61 | HOLD |
| 000756.SZ | Shandong Xinhua Pharmaceutical Company Limited | $1.4B | 62 | HOLD |
| 002550.SZ | Changzhou Qianhong Biopharma CO.,LTD | $1.2B | 66 | BUY |
| 300119.SZ | Tianjin Ringpu Bio-Technology Co.,Ltd. | $1.1B | 55 | HOLD |
| 600557.SS | Jiangsu Kanion Pharmaceutical Co.,Ltd. | $1.1B | 65 | HOLD |
| 600195.SS | China Animal Husbandry Industry Co., Ltd. | $996M | 64 | HOLD |
| 000597.SZ | Northeast Pharmaceutical Group Co., Ltd. | $983M | 64 | HOLD |
| 603456.SS | Zhejiang Jiuzhou Pharmaceutical Co., Ltd | $1.7B | 62 | HOLD |
Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.1%